DNER and prostate neoplasm: We observed that I-BET762 treatment inhibits MYC expression accompanied by the growth inhibition and decreased survival in prostate cancer cells that over-express MYC. Importantly, BET inhibition reduces tumor burden in a primary model of castration resistant prostate cancer that expresses high levels of MYC. Our data suggest that BET inhibitors offer new therapeutic approach to treat prostate tumors driven by MYC.